The Enterprise DG of the European Commission retained Charles River Associates to undertake a study investigating whether there is a worldwide crisis in innovation in the pharmaceutical sector, the reasons behind this crisis, and the tools available to kick-start innovation.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...